January JAAD: Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week randomized, double-blinded, placebo-controlled hase 3 PO
AAD's Dialogues in Dermatology - Un podcast de American Academy of Dermatology
April Armstrong, MD interviewed by Brad Glick, DO, MPH, FAAD
